Adenovirus-assembled DC vaccine induces dual-targeting CTLs for tumor antigen and adenovirus to eradicate tumors

Ding, Jiage; Zheng, Yanyan; Zhu, Fei; Wang, Meng; Fang, Lin; Li, Huizhong; Tian, Hui; Liu, Yong; Wang, Gang; Zheng, Junnian; Chai, Dafei

doi:10.1016/j.intimp.2023.110722

Cited by 4 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An oncolytic adenovirus (OAV-IL-12) was developed to enhance antigen targeting ability of adenovirusassembled DC vaccine (DCs-CD137L/CAIX) for renal carcinoma treatment (Figure 8). [68] Besides, GM-CSF transgene added into the adenoviral genome can increase antitumor therapy. The development of the virus is accompanied by the production of GM-CSF, which results in the maturation of DCs and the priming of T-cells to carry the tumor-associated antigens.…”

Section: Adenovirusmentioning

confidence: 99%

See 2 more Smart Citations

Engineering Microorganisms for Cancer Immunotherapy

Liu,

Yu,

Rong

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Cancer immunotherapy presents a promising approach to fight against cancer by utilizing the immune system. Recently, engineered microorganisms have emerged as a potential strategy in cancer immunotherapy. These microorganisms, including bacteria and viruses, can be designed and modified using synthetic biology and genetic engineering techniques to target cancer cells and modulate the immune system. This review delves into various microorganism‐based therapies for cancer immunotherapy, encompassing strategies for enhancing efficacy while ensuring safety and ethical considerations. The development of these therapies holds immense potential in offering innovative personalized treatments for cancer.This article is protected by copyright. All rights reserved

show abstract

Section: Adenovirusmentioning

confidence: 99%

Section: Herpes Virusmentioning

confidence: 99%